Want to see PRLD full AI Analyst Report?
Prt12396
Primary Myelofibrosis (Pmf), Myelofibrosis (Mf), Myeloproliferative Neoplasms (Mpns), Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, Polycythemia Vera (Pv)
Phase I
Recruiting
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
Feb 26, 2026
―
Pembrolizumab, Prt3789
Advanced Solid Tumor, Metastatic Solid Tumor, Esophageal Cancer, Non-Small Cell Lung Cancers, Smarca4 Gene Mutation
Phase II
Active Not Recruiting
A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
Oct 29, 2024
―
Prt7732
Advanced Solid Tumor, Non-small Cell Lung Carcinoma, Metastatic Solid Tumor, Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma, Smarca4 Mutation, Gastric Squamous Cell Carcinoma, Gastroesophageal Junction Squamous Cell Carcinoma
Phase I
Recruiting
A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
Aug 06, 2024
Venetoclax, Zanubrutinib, Prt2527
Marginal Zone Lymphoma, Acute Myeloid Leukemia (Aml), Myeloid Malignancies, Diffuse Large B-Cell Lymphoma (Dlbcl), T-Cell Lymphoma, Mantle Cell Lymphoma (Mcl), Myelodysplastic Syndrome (Mds), Chronic Myelomonocytic Leukemia (Cmml), Richter's Syndrome, Aggressive B-Cell Non-Hodgkin's Lymphoma (Nhl), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Cll/Sll), Mds/Myeloproliferative Neoplasm (Mpn) Overlap Syndrome
Phase I
Completed
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies
Dec 16, 2022
Docetaxel, Prt3789
Advanced Solid Tumor, Metastatic Solid Tumor, Non-Small Cell Lung Cancers, Smarca4 Gene Mutation
Phase I
Completed
PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation
Nov 11, 2022
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Prelude Therapeutics (PRLD) have in its pipeline
PRLD is currently developing the following drugs: Prt12396, Pembrolizumab, Prt3789, Prt7732. These drug candidates are in various stages of clinical development as the company works toward FDA approval.